Showing 463 results
-
Media Release /PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-…
-
Media Release /Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD…
-
Media Release /- New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark…
-
Media Release /- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1)- Findings…
-
Media Release /- Endpoints met in two Phase III trials, including substantial symptom relief in 84% of systemic juvenile idiopathic arthritis (SJIA) patients treated with ACZ885 in trial-11- SJIA patients treated…
-
Media Release /Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications(1)Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63…
-
Media Release /In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1…
-
Media Release /- 55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults [1]- Additional data presented include analyses on…
-
Media Release /RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and was therefore positive under pre-specified criteriaNewly presented data show that at six months,…
-
Media Release /- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015- FDA Advisory Committee…
